Silexion Therapeutics to Showcase Innovations at BIO Convention
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 09 2026
0mins
Source: PRnewswire
Silexion Therapeutics Corp's stock rose by 5.10% in pre-market trading as it crossed above the 5-day SMA.
The company will attend the 2026 BIO International Convention, where CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar will showcase innovations in RNA interference therapies. Additionally, Silexion's first-generation product demonstrated a positive trend in a Phase 2a clinical trial for KRAS-driven cancers, boosting investor confidence. The company is also advancing its second-generation product candidate SIL204 towards clinical trials in Israel and the EU, targeting locally advanced pancreatic cancer patients.
This participation in a major industry event, along with promising clinical trial results, positions Silexion favorably in the oncology market and may attract potential investors and partners.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLXN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLXN
Wall Street analysts forecast SLXN stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.850
Low
6.00
Averages
9.00
High
12.00
Current: 2.850
Low
6.00
Averages
9.00
High
12.00
About SLXN
Silexion Therapeutics Corp is an Israel-based oncology-focused biotechnology company. The Company is engaged in development of treatments for unsatisfactorily treated solid tumor cancers, which have the mutated KRAS oncogene. The KRAS gene is an oncogene that is involved in regulation of cell division as a result of its ability to relay external signals to the cell nucleus. Based on its research of refractory solid tumor cancers, it is developing a platform focused on the silencing of the KRAS oncogene using ribonucleic acid (RNA)-interference therapeutics. Its lead product candidate, SIL-204B, consists of locally administered small interfering RNAs (siRNA), in an extended-release formulation, as a preferred treatment of locally advanced pancreatic cancer patients, in combination with standard-of-care chemotherapy. Its clinical-stage pipeline is focused on treatment for pancreatic cancer (PC) tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Silexion Receives German Approval for SIL-204 Clinical Trial
- Clinical Trial Approval: Silexion Therapeutics has received approval from the German Federal Institute for Drugs and Medical Devices to conduct a Phase 2/3 trial for SIL-204 targeting locally advanced pancreatic cancer, marking a significant advancement in the fight against this lethal disease.
- Cancer Treatment Potential: With pancreatic cancer having a five-year survival rate below 13% and over 90% of cases exhibiting KRAS mutations, SIL-204, as the company's lead small interfering RNA candidate, aims to target specific KRAS mutations via intratumoral extended-release delivery, showcasing substantial therapeutic potential.
- International Expansion Plans: The trial will be conducted in Germany as the Reporting Member State, with plans to activate clinical testing sites in Israel and other EU member states, indicating the company's intent to expand its international presence, which could enhance its global competitiveness.
- Market Reaction: Silexion's stock closed at $2.71 on Tuesday, up 0.37%, but fell 6.37% to $2.54 in pre-market trading, reflecting a cautious market response to the clinical progress.
See More
Silexion Therapeutics to Attend 2026 BIO International Convention
- Management Attendance: Silexion's CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar will attend the 2026 BIO International Convention in San Diego, CA from June 22-25, showcasing the company's innovations in RNA interference therapies.
- One-on-One Meetings: During the BIO Convention, Silexion's management will host one-on-one meetings aimed at establishing connections with potential investors and partners, thereby advancing the company's strategic collaborations in cancer treatment.
- Clinical Trial Progress: Silexion's first-generation product showed a positive trend in a Phase 2a clinical trial compared to chemotherapy alone, indicating its potential in treating KRAS-driven cancers and enhancing investor confidence.
- Product Candidate Advancement: The company is advancing its second-generation product candidate SIL204 towards clinical trials in Israel and the European Union, aiming to provide new treatment options for locally advanced pancreatic cancer patients, demonstrating its commitment and innovation in oncology.
See More
Silexion Therapeutics Announces 1-for-10 Reverse Stock Split
- Reverse Stock Split Announcement: Silexion Therapeutics has announced a 1-for-10 reverse stock split effective at market close on May 28, 2026, aimed at increasing the share price to comply with Nasdaq's minimum bid price requirement, thereby mitigating delisting risks.
- Par Value Adjustment: Following the reverse split, the par value of ordinary shares will increase from $0.0135 to $0.135 per share, reflecting the company's commitment to shareholder value and compliance in the capital markets.
- Stock Price Reaction: Following the announcement of the reverse split, Silexion Therapeutics' stock price fell by 6.14% to $0.47, indicating that market reactions to this decision may impact investor confidence and future fundraising capabilities.
- Funding Strategy: The company also plans to issue new warrants at $0.50 per share to raise $1 million, a move that will provide necessary liquidity to support its research and operational needs.
See More
Silexion Announces 1-for-10 Reverse Stock Split
- Reverse Split Implementation: Silexion Therapeutics announced a 1-for-10 reverse stock split effective after market close on May 28, 2026, aimed at increasing the per-share trading price to comply with Nasdaq's minimum bid price requirement, thereby enhancing the company's position in the capital markets.
- Shareholder Impact: Following the reverse split, the par value of ordinary shares will rise from $0.0135 to $0.135, with shareholders not needing to take any action as their share counts will be automatically adjusted, ensuring liquidity and market stability.
- Clinical Trial Preparation: Silexion plans to initiate its Phase 2/3 trial of SIL204 this quarter, and the reverse split will provide a stronger foundation for market performance to attract more investors and support its clinical execution.
- Strategic Growth Support: This reverse split is not only to meet Nasdaq compliance but also enhances the company's flexibility for equity financing, aiding Silexion's innovative development in the treatment of KRAS-driven cancers.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Silexion Therapeutics Q1 Earnings Beat Expectations
- Earnings Surprise: Silexion Therapeutics reported a Q1 GAAP EPS of -$0.85, beating expectations by $0.44, indicating an improvement in financial performance despite still being in the red.
- Cash Flow Status: As of March 31, 2026, the company's cash and cash equivalents stood at $2.4 million, down from $6.0 million as of December 31, 2025, primarily due to ongoing operating expenses supporting clinical trial preparations, reflecting continued investment in R&D.
- Clinical Trial Readiness: The cash decrease is mainly attributed to preparations for the Phase 2/3 clinical trial of SIL204, demonstrating the company's commitment to advancing critical R&D projects despite facing funding pressures.
- Financing Initiative: Silexion Therapeutics has priced new warrants at $0.50 each to raise $1 million, aiming to bolster liquidity to support its clinical trials and operational needs.
See More
Silexion Receives German Approval for SIL-204 Clinical Trial
- Clinical Trial Approval: Silexion Therapeutics has received approval from the German Federal Institute for Drugs and Medical Devices to conduct a Phase 2/3 trial for SIL-204 targeting locally advanced pancreatic cancer, marking a significant advancement in the fight against this lethal disease.
- Cancer Treatment Potential: With pancreatic cancer having a five-year survival rate below 13% and over 90% of cases exhibiting KRAS mutations, SIL-204, as the company's lead small interfering RNA candidate, aims to target specific KRAS mutations via intratumoral extended-release delivery, showcasing substantial therapeutic potential.
- International Expansion Plans: The trial will be conducted in Germany as the Reporting Member State, with plans to activate clinical testing sites in Israel and other EU member states, indicating the company's intent to expand its international presence, which could enhance its global competitiveness.
- Market Reaction: Silexion's stock closed at $2.71 on Tuesday, up 0.37%, but fell 6.37% to $2.54 in pre-market trading, reflecting a cautious market response to the clinical progress.
See More
Silexion Therapeutics to Attend 2026 BIO International Convention
- Management Attendance: Silexion's CEO Ilan Hadar and CFO Mirit Horenshtein-Hadar will attend the 2026 BIO International Convention in San Diego, CA from June 22-25, showcasing the company's innovations in RNA interference therapies.
- One-on-One Meetings: During the BIO Convention, Silexion's management will host one-on-one meetings aimed at establishing connections with potential investors and partners, thereby advancing the company's strategic collaborations in cancer treatment.
- Clinical Trial Progress: Silexion's first-generation product showed a positive trend in a Phase 2a clinical trial compared to chemotherapy alone, indicating its potential in treating KRAS-driven cancers and enhancing investor confidence.
- Product Candidate Advancement: The company is advancing its second-generation product candidate SIL204 towards clinical trials in Israel and the European Union, aiming to provide new treatment options for locally advanced pancreatic cancer patients, demonstrating its commitment and innovation in oncology.
See More
Silexion Therapeutics Announces 1-for-10 Reverse Stock Split
- Reverse Stock Split Announcement: Silexion Therapeutics has announced a 1-for-10 reverse stock split effective at market close on May 28, 2026, aimed at increasing the share price to comply with Nasdaq's minimum bid price requirement, thereby mitigating delisting risks.
- Par Value Adjustment: Following the reverse split, the par value of ordinary shares will increase from $0.0135 to $0.135 per share, reflecting the company's commitment to shareholder value and compliance in the capital markets.
- Stock Price Reaction: Following the announcement of the reverse split, Silexion Therapeutics' stock price fell by 6.14% to $0.47, indicating that market reactions to this decision may impact investor confidence and future fundraising capabilities.
- Funding Strategy: The company also plans to issue new warrants at $0.50 per share to raise $1 million, a move that will provide necessary liquidity to support its research and operational needs.
See More
Silexion Announces 1-for-10 Reverse Stock Split
- Reverse Split Implementation: Silexion Therapeutics announced a 1-for-10 reverse stock split effective after market close on May 28, 2026, aimed at increasing the per-share trading price to comply with Nasdaq's minimum bid price requirement, thereby enhancing the company's position in the capital markets.
- Shareholder Impact: Following the reverse split, the par value of ordinary shares will rise from $0.0135 to $0.135, with shareholders not needing to take any action as their share counts will be automatically adjusted, ensuring liquidity and market stability.
- Clinical Trial Preparation: Silexion plans to initiate its Phase 2/3 trial of SIL204 this quarter, and the reverse split will provide a stronger foundation for market performance to attract more investors and support its clinical execution.
- Strategic Growth Support: This reverse split is not only to meet Nasdaq compliance but also enhances the company's flexibility for equity financing, aiding Silexion's innovative development in the treatment of KRAS-driven cancers.
See More
HCW Biologics Stock Surges 129% Amid Concerns
- HCW Biologics Surge: HCW Biologics Inc. (HCWB) saw its stock price soar over 129% to $2.43 on Wednesday, despite concerns about potential cash shortages, with only $1.22 million on hand as of March 31, 2026, which could hinder future R&D efforts.
- Silexion Clinical Progress: Silexion Therapeutics Corp. (SLXN) received approval from the Israeli Ministry of Health to initiate its Phase 2/3 trial for SIL204 in locally advanced pancreatic cancer, with shares rising 96.95% to $0.53, reflecting market confidence in its development prospects.
- Immunovant Positive Data: Immunovant Inc. (IMVT) reported encouraging results from its Phase 2b trial of MVT-1402, with 72.7% of patients showing over 20% symptom improvement after 16 weeks, leading to a 35.26% stock increase to $35.56, indicating strong potential in autoimmune disease treatment.
- Modular Medical Commercialization: Modular Medical Inc. (MODD) received FDA clearance for its next-generation tubeless insulin patch pump, with initial shipments expected by the end of Q2 2026, resulting in an 18.62% stock rise to $3.95, marking a significant step towards commercialization.
See More
Silexion Therapeutics Q1 Earnings Beat Expectations
- Earnings Surprise: Silexion Therapeutics reported a Q1 GAAP EPS of -$0.85, beating expectations by $0.44, indicating an improvement in financial performance despite still being in the red.
- Cash Flow Status: As of March 31, 2026, the company's cash and cash equivalents stood at $2.4 million, down from $6.0 million as of December 31, 2025, primarily due to ongoing operating expenses supporting clinical trial preparations, reflecting continued investment in R&D.
- Clinical Trial Readiness: The cash decrease is mainly attributed to preparations for the Phase 2/3 clinical trial of SIL204, demonstrating the company's commitment to advancing critical R&D projects despite facing funding pressures.
- Financing Initiative: Silexion Therapeutics has priced new warrants at $0.50 each to raise $1 million, aiming to bolster liquidity to support its clinical trials and operational needs.
See More
